Emerging role of multikinase inhibitors for refractory thyroid cancer
Cesar A Perez,1 Belisario A Arango,1 Michel Velez,1 Luis E Raez,2 Edgardo S Santos11University of Miami Miller School of Medicine/Sylvester Comprehensive Cancer Center, Miami, USA; 2Memorial Cancer Institute, Memorial Health Care System, Hollywood, FL, USAAbstract: Thyroid cancer incidence continues...
Saved in:
Main Authors: | Perez CA, Arango BA, Velez M, Raez LE, Santos ES |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/3179f4c79c1e45caa8c0a2a829772923 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib
by: Stjepanovic N, et al.
Published: (2014) -
Multikinase inhibitors use in differentiated thyroid carcinoma
by: Jasim S, et al.
Published: (2014) -
Transferrin receptor-targeted HMSN for sorafenib delivery in refractory differentiated thyroid cancer therapy
by: Ke Y, et al.
Published: (2018) -
Kinase-Inhibitors in Iodine-Refractory Differentiated Thyroid Cancer—Focus on Occurrence, Mechanisms, and Management of Treatment-Related Hypertension
by: Anne Christine Kaae, et al.
Published: (2021) -
Role of vandetanib in the management of medullary thyroid cancer
by: Rondeau G, et al.
Published: (2012)